People: Actelion Ltd (ATLN.VX)

ATLN.VX on Virt-X Level 1

87.70CHF
7:40am EDT
Price Change (% chg)

CHF0.30 (+0.34%)
Prev Close
CHF87.40
Open
CHF87.55
Day's High
CHF88.10
Day's Low
CHF87.45
Volume
200,885
Avg. Vol
603,562
52-wk High
CHF93.45
52-wk Low
CHF52.80

Search Stocks

Summary

Name Age Since Current Position

Jean-Pierre Garnier

66 2011 Chairman of the Board of Directors

Jean-Paul Clozel

58 2000 Chief Executive Officer, Member of the Executive Committee, Delegate to the Board of Directors

Thomas Widman

Co-Founder

Andre Muller

51 2013 Member of the Management Board, Chief Financial Officer, Executive Vice President

Otto Schwarz

58 2011 Member of the Management Board, Chief Operating Officer, Executive Vice President

Guy Braunstein

57 2009 Member of the Management Board, Executive Vice President, Head of Clinical Development

Nicholas Franco

51 2011 Member of the Management Board, Executive Vice President, Chief Business Development Officer

Martine Clozel

58 2009 Member of the Management Board, Senior Vice President, Chief Scientific Officer

Marian Borovsky

44 2003 Member of the Management Board, Senior Vice President, Group General Counsel, Corporate Secretary

Christian Albrich

49 2005 Member of the Management Board, Senior Vice President, Head Global Human Resources

Roland Haefeli

49 2001 Member of the Management Board, Senior Vice President, Head of Investor Relations & Public Affairs

Walter Fischli

64 2009 Senior Vice President Academia Relations

Thomas Weller

Vice President, Co-Head of Drug Discovery

Juhani Anttila

59 2005 Member of the Board of Directors

Robert Bertolini

52 2011 Member of the Board of Directors

Carl Feldbaum

70 2005 Member of the Board of Directors

John Greisch

59 2013 Director

Peter Gruss

64 2012 Member of the Board of Directors

Werner Henrich

70 2000 Member of the Board of Directors

Michael Jacobi

61 2009 Member of the Board of Directors

Armin Kessler

75 2004 Member of the Board of Directors

Jean Malo

60 2004 Member of the Board of Directors

Biographies

Name Description

Jean-Pierre Garnier

Dr. Jean-Pierre Garnier, Ph.D., has been Chairman of the Board of Directors at Actelion Ltd since September 27, 2011. He joined the Company's Board of Directors on May 5, 2011. He is Member of the Compensation Committee, as well as of the Nominating and Governance Committee at the Company. He holds a Doctorate in Philosophy in Pharmacology and a Master of Science degree in Pharmaceutical Science from Louis Pasteur University, Strasbourg, France, as well as a Master of Business Administration degree from Stanford University, California, the United States. During his professional career Dr. Garnier has occupied various management positions at Schering-Plough. Within SmithKline Beecham, he was President of the pharmaceutical business in North America from 1990, elected to the Board of Directors in 1992, Chairman of Pharmaceuticals from 1994, Chief Operating Officer from 1995 and Chief Executive Officer (CEO) from April 2000. He was later First Chief Executive Officer of GlaxoSmithKline between 2001 and2008. Furthermore, he served as CEO of Pierre Fabre Labs in the years 2008 to2010. Apart from his duties to the Company, he is Chairman of the Board of Directors at NormOxys, Inc. and Member of the Board of Directors of United Technologies Corporation and Renault S.A. and of CerenisTherapeutics Inc. He is also Managing partner of Advent International Corporation. He holds Officier de Legion d’Honneur and Knight Commander of the British Empire.

Jean-Paul Clozel

Mr. Jean-Paul Clozel has been Chief Executive Officer, Member of the Executive Committee and Delegate to the Board of Directors of Actelion Ltd since April 2000. He has acted as Chief Financial Officer of the Company since 1999. Mr. Clozel was a practicing cardiologist from 1974 till 1985. He served as Head of Drug Discovery Group in Cardiovascular Department of F. Hoffmann-La Roche from 1985 to 1997, where he was responsible for the selection of T-channel blocker. He also participated in the characterization of renin inhibitors, as well as several endothelin receptor antagonists such as bosentan and clazosentan. He has developed various, novel experimental models allowing the differentiation of these drugs. This work was honored with the 1997 Hoffmann-La Roche Research Prize. In 2007, he was nominated professor at the College de France in Paris and as Chair of Technical Innovation. He obtained a medical degree in France and has further training in pharmacology and psychology at the University of Montreal and the University of California.

Thomas Widman

Mr. Thomas Widman is Co-Founder at Actelion Ltd. A cardiologist educated at Universitat Heidelberg and Paris in Medicine and Computer Science with further training at the University Hospital in Geneva, he later spent seven years at the University of California, San Diego, as Assistant Professor of Medicine and Cardiovascular Associate. During his nine years at F. Hoffmann-La Roche, he was responsible for the worldwide clinical development of the company's cardiovascular portfolio. He was chairman of F. Hoffmann-La Roche's cardiovascular strategy team and led an international cardiovascular development team of over 60 people in Europe and the US. In 1996, he founded Hesperion. Due to his continuing interest in strategic R&D and other management topics, he has also attended business courses at INSEAD.

Andre Muller

Mr. Andre C. Muller has been appointed as Member of the Management Board, Chief Financial Officer, Executive Vice President of Actelion Ltd as of September 1, 2013. He holds an MBA from the Business School E.M. Lyon. He joins Actelion from Pierre Fabre SA, an international pharmaceutical and cosmetic group where he held various position from 1994 until 2011, most recently as Chief Financial Officer.

Otto Schwarz

Mr. Otto Schwarz has been Member of the Management Board, Chief Operating Officer, Executive Vice President of Actelion Ltd since June 7, 2011. He served as Executive Vice President Commercial Operations and Nycomed. He also acted as Member Executive Board Business Strategy & Commercial Operations at Altana Pharma AG. He held various managerial positions at Schering Plough in Austria, Canada, the United States, Germany, and at regional European level, and prior to that with Eli Lilly Austria and Switzerland. He holds a Doctorate in Philosophy degree in Pharmacy/Pharmaceutical Chemistry obtained at Universitaet Wien. Mr. Schwarz completed post-doctoral studies at University of Florida.

Guy Braunstein

Dr. Guy Braunstein has been Member of the Management Board, Executive Vice President, Head of Clinical Development of Actelion Ltd since July 1, 2009. He served as Chief Medical Officer at MerckSerono. In addition, he held the position of Chief Medical Officer at Serono International. He had various executive positions at Astra, Glaxo-Wellcome, GSK, Fisons, Rhone Poulenc Rorer and Chiron. He holds a Doctor of Medicine and Doctorate in Philosophy degree in Life Science from Universite de Paris.

Nicholas Franco

Mr. Nicholas Franco has served as Member of the Management Board, Executive Vice President, Chief Business Development Officer at Actelion Ltd since 2011. He also serves as Senior Vice President, International Commercial Operations, at Axcan Pharma, France; Head of Market Access Region Europe for Novartis Pharma AG, Switzerland, where he held various management positions since 1991. Previous positions include President of Novartis Ophthalmics, Global Head, Business Development and Licensing Negotiations, and Global Head of Neuroscience Business Franchise. He is Graduate of McGill University, Canada, with a BSc in Biochemistry and a Master’s degree in Business Administration, Strategic Planning and Marketing.

Martine Clozel

Ms. Martine Clozel has been Member of the Management Board, Senior Vice President, Chief Scientific Officer at Actelion Ltd since 2009. She has served as Senior Vice President, Head of Drug Discovery, Pharmacology & Pre-clinical Development since 1997. She is one of the founders of the Company. She is Pediatrician specialized in neonatal intensive care, educated at Universite Henri Poincare - Nancy I. She also took training in Physiology and pharmacology at McGill University, Montreal, and at University of California. She was Assistant Professor in Neonatology. She was Scientific Expert, Leader drug discovery projects at F. Hoffman-La Roche.

Marian Borovsky

Mr. Marian Borovsky has been Member of the Management Board, Senior Vice President, Group General Counsel, Corporate Secretary of Actelion Ltd since 2003. He served as Member of the Management Board, Senior Vice President, Group General Counsel from 2000 until 2003 in the Company. He started his professional career as Attorney at Law with an insurance company and subsequently worked as Legal and Tax Adviser for PricewaterhouseCoopers. In addition, he completed a secondment to an international business law firm in London, the United Kingdom. He holds a Juris Doctor degree from Universitaet Basel. He is Attorney at Law admitted to the Bar in Switzerland and is also qualified business mediator.

Christian Albrich

Mr. Christian Albrich has served as Member of the Management Board, Senior Vice President, Head Global Human Resources at Actelion Ltd since 2005. He previously was Human Resources Manager at Boehringer Ingelheim in France, as well as HR Director at Serono for European countries. He joined Actelion in 2002 as Head of HR for Europe, Canada and Latin America.

Roland Haefeli

Mr. Roland Haefeli has served as Member of the Management Board, Senior Vice President, Head of Investor Relations & Public Affairs at Actelion Ltd from 2001. He served for several years as News Writer, Presenter and Editor for several print and electronic media operations. He has served as Delegate for International Committee of the Red Cross (ICRC) for two years. He was Corporate Spokesperson for F. Hoffman-La Roche and Head of Media Relations for other companies, including Serono. He obtained advanced degrees in Contemporary History from University of Bern and in Political Science from University of North Carolina.

Walter Fischli

Mr. Walter Fischli has been Senior Vice President Academia Relations at Actelion Ltd since July 1, 2009. He is one of the founders of the Company. He was Member of a research fellowship at Addiction Research Foundation at Stanford University. He has experience in drug discovery at F. Hoffmann-La Roche. He served as Head of Drug Discovery, Molecular Biology & Biochemistry from 1997 till June 2009. He is a Biochemist educated at Edgenoessische Technische Hochschule in Zurich (ETH) (Swiss Federal Institute of Technology, Zurich) with further training in molecular biology and organic chemistry.

Thomas Weller

Juhani Anttila

Mr. Juhani Anttila has been Member of the Board of Directors of Actelion Ltd since 2005. He served as Managing Partner at CA Corporate Advisers from 1981 till 1985. He is Member of the Finance and Audit Committee of the Company. He served as Managing Director of Nokia GmbH from 1985 to 1988. Between 1989 and 1995 he served as Member of the Executive Board of Nokia Consumer Electronics Division. He acted as Chairman of the Executive Board of Nokia (Deutschland) GmbH from 1990 till 1995. Afterwards he held the position of President and Chief Executive Officer of the Swisslog Holding Ltd from 1996 until 2002. He served as Chief Executive Officer of Ascom Holding Ltd from 2003 till 2004. Since 2004 he has been Managing Director of ValCrea AG. He is also Chairman of the Board of Directors of ArgYou AG, Ascom Holding Ltd and ValCrea AG. He holds a Masters degree, obtained in 1978, and a Bachelors degree, obtained in 1976, in Law from the Helsingin yliopisto.

Robert Bertolini

Mr. Robert (Bob) J. Bertolini is Member of the Board of Directors at Actelion Ltd since May 5, 2011. He is Member of the Finance and Audit Committee at the Company. He holds a Bachelor of Arts degree in Economics from the Rutgers State University of New Jersey. He is a Certified Public Accountant licensed in New York and New Jersey, the United States. He is a Former Executive Vice President and Chief Financial Officer at Schering Plough Corporation. He has held various executive positions at PriceWaterhouseCoopers and is former Member of the Board of Directors of Genzyme Corporation. Apart from his duties at the Company, Mr. Bertolini is Member of the Board of Directors at Charles River Laboratories International, Inc. and at ElectroCore, Inc.

Carl Feldbaum

Mr. Carl B. Feldbaum has been Member of the Board of Directors of Actelion Ltd since 2005. He is Chairman of the Nominating and Governance Committee of the Company. After graduation, he went to Washington, in 1973, as Assistant Special Prosecutor for the Watergate special prosecution force, where he served until 1975. He was President of the Biotechnology Industry Organization (BIO) in Washington, D.C. from its founding in 1993 to January 2005. Earlier roles concluded President and Founder of the Palomar Corporation, a national security think tank in Washington, D.C. He also served as Assistant to the Secretary of Energy and as Inspector General for defense intelligence in the United States Department of Defense between 1979 and 1980. In addition, he acted as Chief of Staff to Senator Arlen Specter of Pennsylvania from 1988 to 1993. In 1979, he was awarded the Distinguished Civilian Service Medal by Defense Secretary Harold Brown. He is Member of the Board of Directors of Exelexis Inc., as well as Chairman of the Board of BIO Ventures for Global Health. He holds a Bachelors degree in Biology from Princeton University and a Law degree from the University of Pennsylvania Law School.

John Greisch

Mr. John J. Greisch has served as Member of the Board of Directors at Actelion Ltd since April 18, 2013. He holds Bachelor’s degree in Business Administration from the Miami University, Oxford, Ohio, US; Master’s Degree in Management (MBA equivalent) from the JL Kellogg Graduate School of Management. Previously, he served as CFO (2004-2006) and President, International Operations (2006- 2009) at Baxter International, Inc., as currently serves as President and CEO of Hill- Rom Holdings, Inc., since 2010.

Peter Gruss

Prof. Dr. Peter Gruss serves as Member of the Board of Directors of Actelion Ltd since May 4, 2012. He also is Member of the Nominating and Governance Committee of the Company. He is President of the Max Planck Society in Munich, Germany (since 2002), Director at the Max Planck Institute for Biophysical Chemistry in Goettingen, Germany (since 1986), Honorary Professor at the University of Goettingen, Germany. He also serves as Member of the Board of Directors of the listed companies Siemens AG and Munich Re, Member of the Advisory Board of Deloitte, Member of the “Innovation Dialogue” of the Federal Chancellery, Member of the Senates of the Alliance of Scientific Organizations in Germany, the German Research Foundation (DFG), the German National Academy of Sciences (Leopoldina) and National Academy of Science and Engineering (acatech). He holds Ph.D. in Biology from the Universitat of Heidelberg, Germany.

Werner Henrich

Mr. Werner Henrich has been Member of the Board of Directors of Actelion Ltd since 2000. He is Member of the Compensation Committee of the Company. He is a former Head of Global Intellectual Property and Licensing at F. Hoffmann-La Roche Ltd. He is also Chairman of the Board of Basilea Pharmaceutica Ltd. He is Chairman of the Board of Directors of PregLem SA and Member of the Board of Directors of TET Systems AG, PharmaSens AG and is also Chief Executive Officer of Pivalor AG. He graduated as Chemist and European Patent Attorney.

Michael Jacobi

Dr. Michael Jacobi has been Member of the Board of Directors of Actelion Ltd since April 24, 2009. He is Chairman of the Finance and Audit Committee of the Company. He undertook additional studies at University of Washington and completed a Program for Management Development at Harvard Business School. He joined the Ciba Group in 1978, and subsequently held various executive positions in the financial area in Switzerland, Brazil and the United States. He is a former Chief Financial Officer at Ciba Speciality Chemicals Inc, a position he held from 1996 till 2007. He is Member of the Board of Directors of Sonova Holding AG and Hilti AG, as well as Member of the Board of Trustees of the Martin Hilti Family Trust. He holds a Doctorate in Philosophy degree in Business Administration from Universitaet St. Gallen (HSG). He has attended additional studies at the University of Washington, Seattle, the United States, and completed a Program for Management Development at Harvard Business School, Boston.

Armin Kessler

Mr. Armin M. Kessler has been Member of the Board of Directors of Actelion Ltd since 2004. He is Chairman of the Compensation Committee and Member of the Nominating and Governance Committee of the Company. He served as Chief Operating Officer of F. Hoffmann-La Roche Ltd from 1990 till 1995. Prior to that appointment, he held senior management positions at Roche, including Head of Diagnostics and Pharmaceutical divisions. Earlier positions included Director of Pharmaceutical Marketing Worldwide at Sandoz (now Novartis) and President of Sandoz KK in Tokyo. He served also on the Board of Syntex Chemicals, Genentech and F. Hoffmann-La Roche. He is also Vice Chairman of the Board of Directors and Lead Director of Gen-Probe Inc. He is Member of the Board of Directors of The Medicines Co. and MedGenesis Therapeutix Inc, as well as Vice Chairman and Lead Director of Gen-Probe Inc. He holds a degree in Physics and Chemistry from Pretoria University in South Africa, degree in Chemical Engineering from the University of Cape Town and Juris Doctor title from Seton Hall University. He is registered Patent Attorney at the United States Patent Office.

Jean Malo

Mr. Jean P. Malo has been Member of the Board of Directors of Actelion Ltd since 2004. He is Member of the Finance and Audit Committee of the Company. Mr. Malo served as Senior Partner and Chief Investment Officer at Breen Investors LP from 2000 till 2008. Prior to that, he served as Chief Investment Officer for Vaughan Nelson Scarborough and McCullough, including managing several equity portfolios between 1997 and 2000. From 1989 till 1997, he managed both equity and fixed income portfolios for Daniel Breen and Company. From 1978 till 1989, he acted as Corporate Banker for Banque Indosuez. From 1977 till 1978, he held the position of Financial Analyst at French Embassy in Singapore. He is also Founding Partner of Houston Global Investors LLC. He graduated with an Masters of Business Administration degree from ESSEC Business School in 1977. He is Chartered Financial Analyst and Member of the Association for Investment Management and Research and the Houston Society of Financial Analysts.
Search Stocks